Introduction
This is a Phase II, prospective, multi-center, randomized, open label, parallel group study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations. A total of 176 patients in Germany will be included in the study. The detection of a germline mutation in BRCA1/2 is a prerequisite for screening for the study.
News
Patient recruitment started in October 2024.
You are welcome to refer a patient to one of our trial sites. Interested physicians can view an overview of all participating sites on the new Reesi platform.
Here you will find the link to the login area.
GBG Mamma Mia special print
New studies on hormone receptor-positive, HER2-negative breast cancer in the special print of Mamma Mia
The inclusion and exclusion criteria as well as more detailed information on the study design are available on request.
Contact
Dr. Laura Steinmann
